The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03417102




Registration number
NCT03417102
Ethics application status
Date submitted
25/01/2018
Date registered
30/01/2018
Date last updated
21/01/2019

Titles & IDs
Public title
A Study of Fitusiran (ALN-AT3SC) in Severe Hemophilia A and B Patients With Inhibitors
Scientific title
ATLAS-INH: A Phase 3 Study to Evaluate the Efficacy and Safety of Fitusiran in Patients With Hemophilia A or B, With Inhibitory Antibodies to Factor VIII or IX
Secondary ID [1] 0 0
2016-001463-36
Secondary ID [2] 0 0
EFC14768
Universal Trial Number (UTN)
Trial acronym
ATLAS-INH
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Hemophilia A 0 0
Hemophilia B 0 0
Condition category
Condition code
Blood 0 0 0 0
Clotting disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - fitusiran
Treatment: Drugs - recombinant Factor VIIa and FEIBA

Experimental: fitusiran -

Active Comparator: On demand bypassing agents -


Treatment: Drugs: fitusiran
by subcutaneous (SC) injection

Treatment: Drugs: recombinant Factor VIIa and FEIBA
by intravenous (IV) injection

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Annualized bleeding rate (ABR)
Timepoint [1] 0 0
9 months
Secondary outcome [1] 0 0
Annualized spontaneous bleeding rate
Timepoint [1] 0 0
9 months
Secondary outcome [2] 0 0
Annualized joint bleeding rate
Timepoint [2] 0 0
9 months
Secondary outcome [3] 0 0
Quality of Life (QOL) as measured by Haem-A-QOL Questionnaire score on a scale of 0-100 with higher scores representing greater impairment.
Timepoint [3] 0 0
9 months

Eligibility
Key inclusion criteria
- Males, =12 years of age

- Severe hemophilia A or B with inhibitors

- (Severity confirmed by a central laboratory where FVIII level is <1% or FIX level
is =2% at Screening; Inhibitors defined as inhibitor titer of =0.6 BU/mL or as
evidenced by medical records)

- A minimum of 6 bleeding episodes requiring bypassing agent treatment within the last 6
months prior to Screening

- Willing and able to comply with the study requirements and to provide written informed
consent and assent
Minimum age
12 Years
Maximum age
No limit
Gender
Males
Can healthy volunteers participate?
No
Key exclusion criteria
- Known co-existing bleeding disorders other than hemophilia A or B

- Antithrombin (AT) activity <60% at Screening

- Co-existing thrombophilic disorder

- Clinically significant liver disease

- Active HCV infection

- HIV positive with a CD4 count of <200 cells/µL

- History of arterial or venous thromboembolism

- Inadequate renal function

- History of multiple drug allergies or history of allergic reaction to an
oligonucleotide or N-Acetylgalactosamine (GalNAc)

- History of intolerance to SC injection(s)

- Any other conditions or comorbidities that would make the patient unsuitable for
enrollment or could interfere with participation in or completion of the study, per
Investigator judgement

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
Recruitment hospital [1] 0 0
Clinical Trial Site - Melbourne
Recruitment postcode(s) [1] 0 0
3004 - Melbourne
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Florida
Country [4] 0 0
United States of America
State/province [4] 0 0
Louisiana
Country [5] 0 0
United States of America
State/province [5] 0 0
Nevada
Country [6] 0 0
United States of America
State/province [6] 0 0
North Carolina
Country [7] 0 0
United States of America
State/province [7] 0 0
Ohio

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Genzyme, a Sanofi Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to determine the frequency of bleeding episodes in patients
receiving fitusiran as prophylactic treatment of hemophilia compared with patients who are
assigned to continue with their regular medication. In addition, the study will assess
safety, quality of life, pharmacodynamics (PD), and pharmacokinetics (PK).
Trial website
https://clinicaltrials.gov/show/NCT03417102
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Clinical Sciences & Operations, MD
Address 0 0
Sanofi
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Trial Transparency email recommended (Toll free number for US & Canada)
Address 0 0
Country 0 0
Phone 0 0
800-633-1610
Fax 0 0
Email 0 0
Contact-US@sanofi.com
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Not applicable